secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2026-06-09T21:04:50+00:00
Accession:  0001193125-26-264000
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyntra Bio receives final $4M holdback from AstraZeneca for China ops sale
--------------------------------------------------------------------------

- Received $4.0M from AstraZeneca, satisfying final holdback under February 2025 share purchase agreement.
- Total consideration for sale of China operations was ~$220M ($85M enterprise value + ~$135M net cash).
- Previously received $6.0M holdback plus $0.4M net cash adjustment payment in November 2025.
- With this payment, all owed amounts under the Share Purchase Agreement have been collected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000119312526264000/0001193125-26-264000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000119312526264000/kynb-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-264000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer